Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Federico Innocenti

Showing results (61-70 of 186) with videos related to

Pageof 19
Sort By:
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomesJacqueline Ramírez, Federico Innocenti, Erin G Schuetz, et al.
Scientific Reports|September 7, 2022
A resource for integrated genomic analysis of the human liverYi-Hui Zhou, Paul J Gallins, Amy S Etheridge, et al.
British Journal of Clinical Pharmacology|April 19, 2022
Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitorsJulia C F Quintanilha, Kelli Hammond, Yingmiao Liu, et al.
Cancer Research|January 25, 2005
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoterWanqing Liu, Federico Innocenti, Michael H Wu, et al.
Pharmacogenetics|December 5, 2002
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groupsFederico Innocenti, Carrie Grimsley, Soma Das, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2004
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancerApurva A Desai, Federico Innocenti, Linda Janisch, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 7, 2013
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimensEric Lévesque, Anne-Sophie Bélanger, Mario Harvey, et al.
Clinical Pharmacology and Therapeutics|November 13, 2004
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbitalFederico Innocenti, Samir D Undevia, Jacqueline Ramírez, et al.
Pharmacogenetics and Genomics|September 10, 2015
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patientsSylvia Chen, Lyne Villeneuve, Derek Jonker, et al.
Clinical Pharmacology and Therapeutics|April 25, 2022
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical FactorsSpinel Karas, Ron H J Mathijssen, Ron H N van Schaik, et al.
Pageof 19

Showing results (61-70 of 186) with videos related to

Sort By:
Pageof 19
Drug Metabolism and Disposition: the Biological Fate of Chemicals|August 21, 2004
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomesJacqueline Ramírez, Federico Innocenti, Erin G Schuetz, et al.
Scientific Reports|September 7, 2022
A resource for integrated genomic analysis of the human liverYi-Hui Zhou, Paul J Gallins, Amy S Etheridge, et al.
British Journal of Clinical Pharmacology|April 19, 2022
Plasma levels of VEGF-A and VCAM-1 as predictors of drug-induced hypertension in patients treated with VEGF pathway inhibitorsJulia C F Quintanilha, Kelli Hammond, Yingmiao Liu, et al.
Cancer Research|January 25, 2005
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoterWanqing Liu, Federico Innocenti, Michael H Wu, et al.
Pharmacogenetics|December 5, 2002
Haplotype structure of the UDP-glucuronosyltransferase 1A1 promoter in different ethnic groupsFederico Innocenti, Carrie Grimsley, Soma Das, et al.
Cancer Chemotherapy and Pharmacology|July 6, 2004
A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancerApurva A Desai, Federico Innocenti, Linda Janisch, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 7, 2013
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimensEric Lévesque, Anne-Sophie Bélanger, Mario Harvey, et al.
Clinical Pharmacology and Therapeutics|November 13, 2004
A phase I trial of pharmacologic modulation of irinotecan with cyclosporine and phenobarbitalFederico Innocenti, Samir D Undevia, Jacqueline Ramírez, et al.
Pharmacogenetics and Genomics|September 10, 2015
ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patientsSylvia Chen, Lyne Villeneuve, Derek Jonker, et al.
Clinical Pharmacology and Therapeutics|April 25, 2022
Model-Based Prediction of Irinotecan-Induced Grade 4 Neutropenia in Advanced Cancer Patients: Influence of Demographic and Clinical FactorsSpinel Karas, Ron H J Mathijssen, Ron H N van Schaik, et al.
Pageof 19